| abstract |
The present invention is for the treatment of urological disorders, including benign prostatic hypertrophy (BPH), lower urinary tract symptoms (LUTS), and irritation symptoms, particularly due to BPH-induced subvesical urethral obstruction (BOO). Pharmaceutical compositions comprising PDE-5 and PDE-4 inhibitors alone or in combination are provided. The present invention also provides methods of screening for such PDE-5 and PDE-4 inhibitors for use alone or in combination in the manufacture of a medicament for the treatment of the urological disorder. |